Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective IMRT with Panitumumab for Head and Neck Cancer
NCT01312493Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2011
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Recurrence Rate of Locally Advanced Head & Neck Cancer at 2 years. Planned start Dec 2011; status: withdrawn.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01312493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312493.